Patent · US Active

Kinase inhibitors

US10752624B2 · kind B2 · utility

0Cited by

4References

7Claims

0Family size

Assignee

Origenis GMBH · DE

Inventors

Michael Almstetter · Martinsried, DE
Michael Thormann · Martinsried, DE
Andreas Treml · Martinsried, DE
Roland Koestler · Martinsried, DE
Nasser Yehia · Martinsried, DE

Key dates

Filing date	May 18, 2018
Grant date	Aug 25, 2020
Priority date	—
Expiry date	May 18, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.